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We are pleased to learn that AlBugami et al1 conﬁrm our most
important ﬁnding: catheter design has little, if any, inﬂuence on
catheter survival and incidence of thrombosis/infection. In our
large sample (.60,000 catheter-days), we used the strict pre-
emptive catheter salvage KDOQI (Kidney Disease Outcomes
Quality Initiative) protocol, which resulted in relatively low uro-
kinase use (17-35 episodes/1,000 catheter-days).2 AlBugami et al
used 2 mg (lock) or 4 mg (infusion) of tissue plasminogen acti-
vator when blood ﬂow rate was ,250 mL/min (M.M. AlBugami,
personal communication, March 2015), corresponding with an
average of 70 locks or 35 infusions/1,000 catheter-days. Com-
paring thrombolysis outcome across both studies is very difﬁcult
in view of the differences in indication, administration mode, and
type of thrombolytic. However, we believe that our pre-emptive
strategy is efﬁcient and cost-effective and over-rides any poten-
tial initial differences in catheter costs.
The question from Drs Ashby and Corbett3 most likely orig-
inates from a difference in interpretation of the concept of
censoring. An observation is “censored” when the observation
time has been interrupted prematurely and the time to event (in
our case, thrombosis/infection) has therefore not been registered.
Because our study reﬂected standard clinical practice, there was a
high degree of early censoring (recovery of kidney function,
maturation of vascular access, and transfer to peritoneal dialysis
therapy). Primary assisted patency was deﬁned as the interval
from access placement to catheter removal for infection/throm-
bosis, with censoring for non–catheter-related removal.2 This is
entirely different from mean survival time (time to thrombosis/
infection if all catheters had been followed up until the throm-
bosis/infection end point was reached), of which the Kaplan-
Meier curve gives only a poor estimate given the high degree
of censoring.4
An De Vriese, MD, PhD1
Hans Van Der Meersch, MD1
Dirk De Bacquer, PhD2
1AZ Sint-Jan Brugge, Brugge, Belgium
2Ghent University, Ghent, Belgium
Acknowledgements
Financial Disclosure: The authors declare that they have no
relevant ﬁnacnial interests.
References
1. AlBugami MM, Tennankore KK, Soroka SD. Hemodialysis
catheters: which design is more cost-effective? Am J Kidney Dis.
2015;66(1):170.
2. Van Der Meersch H, De Bacquer D, Vandecasteele SJ, et al.
Hemodialysis catheter design and catheter performance: a ran-
domized controlled trial. Am J Kidney Dis. 2014;64(6):902-908.
3. Ashby DR, Corbett RW. Use of an uncensored primary
outcome in a catheter design trial? Am J Kidney Dis. 2015;66(1):
170.
4. Altman DG. Summarizing survival. In: Practical Statistics
for Medical Research. London, UK: Chapman & Hall / CRC
Press; 1991:386.
Originally published online May 19, 2015.
 2015 by the National Kidney Foundation, Inc.
http://dx.doi.org/10.1053/j.ajkd.2015.04.008Am J Kidney Dis. 2015;66(1):170-177The Myth of the Future Burden of CKD
in United States
To the Editor:
We read with interest the article by Hoerger et al about the
future burden of CKD in the United States.1 These authors accept
the notion that as humans age, glomerular ﬁltration rate (GFR)
falls.2-4 Consequently, the application of a ﬁxed and arbitrary
threshold of GFR as a deﬁnition for “CKD,” without reference to
other signs of kidney damage (such as albuminuria) will always
lead to increased “CKD” prevalence as populations age.5 Without
an age-adapted deﬁnition, the prevalence of CKD is over-
estimated, with a high proportion of the elderly in stage 3a.6
Prognosis is now considered as a key feature of CKD classiﬁca-
tion; however, it has been shown that remaining life expectancy
is not different between individuals in CKD stage 3a versus
those with normal kidney function (see the second ﬁgure in
Gansevoort et al7).
If Hoerger et al wish to suggest that individuals can expect
a 1 in 2 chance of developing CKD over their lifetimes, they
should make the association of CKD risk and aging clearer.
Also they need to explain the gap in “CKD” prevalence be-
tween stage 3a (around 20% of population older than 65 years
of age) and stages 3b (8%) or 4-5 (,3%); clearly stage 3a
neither progresses to more severe stages nor shortens life
expectancy.7
A solution would be to age calibrate the thresholds of estimated
GFR used to deﬁne CKD in absence of other signs of kidney
damage.8 Then, the alarming prospects of the simulation from
Hoerger et al would take a more subtle and less dramatic hue.
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Burden of CKD in United States’
In our AJKD article, we reported estimates of the future
prevalence of CKD using existing deﬁnitions of the disease.1 In
their letter, Drs Delanaye, El Nahas, and Glassock state that the
high prevalence of CKD in persons aged 65 and older is pri-
marily due to aging and does not represent an added mortality
risk.2 A few studies have indeed found that estimated GFR
values between 45 and 59 mL/min/1.73 m2 are not associated
with increased mortality.3 However, other large epidemiologic
studies have found that the relative and absolute risks of mor-
tality are higher for the elderly with estimated GFR in this
range than for the elderly with greater estimated GFR levels,
even after controlling for albuminuria.4,5 Thus, we believe that
CKD staging does provide prognostic information for persons
aged 65 and older. We agree with Delanaye et al that not all
persons who reach CKD stage 3a will progress to more
advanced CKD stages; however, we disagree with their state-
ment that “clearly stage 3a neither progresses to more severe
stages nor shortens life expectancy” in persons aged 65 and
older.
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http://dx.doi.org/10.1053/j.ajkd.2015.05.003172Discontinuation of Eculizumab Treatment
in Atypical Hemolytic Uremic Syndrome:
An Update
To the Editor:
We write to update our previously published report of dis-
continuing eculizumab therapy after successful treatment of
atypical hemolytic uremic syndrome in 10 patients,1 with
longer-term follow-up of the original cases and a report of 6
additional cases. When stable clinical remission had been ob-
tained, patients were offered the choice of continuing or dis-
continuing eculizumab treatment with the rationale and
procedure previously described.1 Patients had received eculi-
zumab for a median of 4.3 (range, 0.5-14.4) months (Table 1).
Eight were able to discontinue dialysis therapy, whereas the
other 8 had never been dialyzed. During a cumulative time off
treatment of 243 months, 5 patients experienced relapse, iden-
tiﬁed by means of regular home urine dipstick testing, within 6
months of the last eculizumab dose (an average of 1 relapse per
49 months off therapy). In these patients, eculizumab therapy
was restarted, followed by rapid improvement in serum creati-
nine levels and proteinuria to or below baseline values, and
maintained every 3 or 4 weeks based on global complement
activity.2 Eleven patients remained in remission with no signs
of acute disease.
In conclusion, we believe that in atypical hemolytic uremic
syndrome, it is possible and relatively safe to discontinue
eculizumab therapy. In general, we discourage discontinuation
of eculizumab therapy in kidney transplant recipients with CFH
mutations and patients with glomerular ﬁltration rates , 20 mL/
min/1.73 m2. In patients with anti-CFH antibodies, we consider
discontinuation of eculizumab therapy when antibody titer
is ,2.5 times the upper limit of normal. We suggest regular
home urine dipstick monitoring for early identiﬁcation of re-
lapses, especially during acute illnesses and when patients feel
unwell.
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